LA JOLLA, Calif., March 30 /PRNewswire-FirstCall/ -- Transdel Pharmaceuticals, Inc. , a specialty pharmaceutical company focused on developing and commercializing non-invasive, topically administered medications, has recently expanded its product development programs to include cosmetic /cosmeceutical products utilizing the company’s patented Transdel(TM) delivery technology. This new product line includes an anti-cellulite product, which addresses a very large demand in the marketplace.
For the Company’s anti-cellulite product, the Company now has initial clinical information supporting the efficacy of this key product. Transdel is currently in discussions with potential sales and marketing partners for this product and is targeting to introduce it into the market in 2009. The Company’s potential pipeline of other cosmetic/cosmeceutical products, for which it is pursuing discussions with potential partners, includes anti-aging, varicose vein and hyperpigmentation formulations.
“The cosmeceutical products we are developing and testing are exciting prospects for Transdel,” said Dr. Juliet Singh, President and CEO of Transdel. “A significant market opportunity exists for effective cosmetic and cosmeceutical products, especially for an anti-cellulite product. Given the right sales and marketing partner and considering the potentially faster time to market for such products, we believe that entry into the cosmetic/cosmeceutical space holds tremendous potential for the Company.”
About Transdel Pharmaceuticals, Inc.
Transdel Pharmaceuticals, Inc. is a specialty pharmaceutical company developing non-invasive, topically delivered medications. The Company’s innovative-patented Transdel(TM) cream formulation technology is designed to facilitate the effective penetration of drugs through the tough skin barrier to reach the target underlying tissues. In the case of Ketotransdel(R), the Transdel(TM) cream allows the active ingredient ketoprofen, a non steroidal anti-inflammatory drug, to reach the target soft tissue and exert its well-known anti-inflammatory and analgesic effects. The Company is also investigating other drug candidates and treatments for transdermal delivery using the Transdel(TM) platform technology for products in pain management and other therapeutic areas and for cosmetic/cosmeceutical products. For more information, please visit http://www.transdelpharma.com.
Safe Harbor Statement
Statements made in this release that are not historical in nature constitute forward-looking statements within the meaning of the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by the use of words such as “expects,” “plans,” “will,” “may,” “anticipates,” “believes,” “should,” “intends,” “estimates,” and other words of similar meaning. These statements are subject to risks and uncertainties that cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with the uncertainty of future financial results, additional financing requirements, development of new products, government approval processes, the impact of competitive products or pricing, and technological changes. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company’s filings with the Securities and Exchange Commission, including the Company’s Annual Report on Form 10-K filed with the SEC on March 26, 2009. Such documents may be read free of charge on the SEC’s web site at www.sec.gov. All forward-looking statements included in this release are made as of the date of this press release, and the Company assumes no obligation to update any such forward-looking statements.
CONTACT: John Lomoro, CFO, Transdel Pharmaceuticals, Inc.,
+1-858-457-5300, johnl@transdelpharma.com
Web site: http://www.transdelpharma.com/
